Skip to main content
SpringerLink
Log in

Bromocriptine and lactation suppression: Are the risks acceptable?

  • Editorial
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Herings RMC, Stricker BHC. Bromocriptine and suppression of postpartum lactation. The incidence of adverse cardiovascular effects in women of child-bearing age. Pharm World Sci 1995;17:133–7.

    PubMed  Google Scholar 

  2. US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel); withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60:3404–5.

    Google Scholar 

  3. Health Canada, Drugs Directorate. Bromocriptine and lactation suppression. Can Adverse Drug React Newsletter 1995;5:66–7.

    Google Scholar 

  4. US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel) for the prevention of physiological lactation; opportunity for a hearing on a proposal to withdraw of approval of the indication. Fed Reg 1994;59:43347–52.

    Google Scholar 

  5. McCarthy M. Bromocriptine not for lactation suppression. Lancet 1994;344:602.

    Google Scholar 

  6. Rothman KJ, Funch DP, Dreyer NA. Bromocriptine and puerperal seizures. Epidemiology 1990; 1:232–8.

    PubMed  Google Scholar 

  7. Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989;74:448–51.

    PubMed  Google Scholar 

  8. Mallarkey G. Bromocriptine in lactation suppression: is there cause for concern? Curr Ther 1995:103–6.

  9. Fournié A, Graile V, Montastruc JL. Bromocriptine, lactation inhibition and pharmacovigilance. J Gynecol Obstet Biol Reprod 1994;23:129–30.

    Google Scholar 

  10. Moride Y, Haramburu F, Bégaud B. Assessment of under-reporting of adverse events in pharmacovigilance. Pharmacoepidemiol Drug Saf 1994;3:S73.

    Google Scholar 

  11. Bromocriptine (Parlodel®) niet voor lactatieremming [Bromocriptine not for lactation suppression]. Geneesmiddelenbulletin 1994;28:84–5.

  12. Zerebrale und kardiovaskulare Storwirkungen nach Abstillen met Bromocriptin (Pravidel). Arznei-telegramm 1995;3:27.

    Google Scholar 

  13. Mignot G. Inhibition de la lactation apres l'accounchement. Rev Prescrire 1995;15:440–5.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Social Pharmacy and Pharmacoepidemiology, Croningen Institute of Drug Studies, State University Groningen, Ant. Deusinglaan 2, 9713, AW Groningen, the Netherlands

    Lolkje de Jong-van den Berg

  2. Health Action International Europe, Jacob van Lennepkade 334-1, 1053, NJ Amsterdam, the Netherlands

    Barbara Mintzes B.A.

Authors
  1. Lolkje de Jong-van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara Mintzes B.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Jong-van den Berg, L., Mintzes, B. Bromocriptine and lactation suppression: Are the risks acceptable?. Pharm World Sci 17, 93–95 (1995). https://doi.org/10.1007/BF01872384

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01872384

Keywords

Search

Navigation